Sign In
Buy BAYRY
$10.81
+0.248 (+2.35%)
At Close: Jun 22, 2026
Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada
03:22pm, Thursday, 18'th Jun 2026
CALGARY, Alberta--(BUSINESS WIRE)--The Crop Science division of Bayer announced that Kacy Perry has been appointed the Country Division Head (CDH) for Crop Science Canada, effective July 1. In this ro
Federal judge sends Bayer's $7.25 billion Roundup settlement back to Missouri state court
11:17am, Wednesday, 17'th Jun 2026
A federal judge on Wednesday returned Bayer's proposed $7.25 billion settlement of Roundup lawsuits to Missouri state court, overruling the objections of some cancer victims who said the stat
Bayer (BAYRY) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 15'th Jun 2026
Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention
11:22am, Thursday, 11'th Jun 2026
BAYRY's asundexian enters EMA review for stroke prevention after phase III data showed a 26% cut in ischemic stroke without more major bleeding.
Bayer hopes to speed up biofuel feedstock plan amid Iran war energy crunch
01:43pm, Wednesday, 10'th Jun 2026
Bayer is hoping to speed up a plan to facilitate North American production of biofuel feedstocks like camelina in the wake of the Iran war, the drug-making and crop science giant said on Wednesday.
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 08'th Jun 2026
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Bayer Aktiengesellschaft (BAYRY) and Roche Holding AG (RHHBY). But which of these two stocks presents invest
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
08:00am, Monday, 08'th Jun 2026
BASEL, Switzerland & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further en
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney dis
Bayer Says 'Not Now' To Monsanto Spin-Off Amid Ongoing Roundup Legal Battle
04:32am, Wednesday, 03'rd Jun 2026
Bayer rules out a Monsanto spin-off despite mounting Roundup lawsuits that continue to pressure the company.
Bayer says no plans to restructure despite litigation threat
07:11pm, Tuesday, 02'nd Jun 2026
Bayer has no plans to spin off Monsanto, a representative said on Tuesday, even as the company faces an avalanche of lawsuits over its Roundup weedkiller.
WHIPPANY, N.J.--(BUSINESS WIRE)--Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with
Bayer sued for allegedly monopolizing US market for GMO corn seeds
05:54pm, Wednesday, 27'th May 2026
Bayer used illegal and anti-competitive practices to monopolize the U.S. market for genetically engineered corn seeds, reaping "hundreds of millions, if not billions, of ill-gotten dollars," accord
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
09:51am, Tuesday, 26'th May 2026
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
BAYRY's Kerendia Label Expansion Application Gets Priority Review
02:00pm, Thursday, 21'st May 2026
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
Bayer says FDA grants priority review designation for finerenone
02:56am, Thursday, 21'st May 2026
Bayer said on Thursday that the U.S. Food and Drug Administration had accepted its supplemental New Drug Application for finerenone and granted priority review designation.
